MDMA

Ecstasy6, Molly21, Methylsafrylamin6, XTC6, E6, Adam6, EA-14756

MDMA, also known as 3,4-methylenedioxymethamphetamine, is a synthetic recreational psychoactive drug first developed by Merck in 1912.1 The original name Merck gave MDMA was methylsafrylamin. MDMA started becoming available to the public and appearing on the streets in the US in the 1970s in Illinois2,3 and Indiana.4

Some sources report that Merck initially synthesized MDMA as part of their research and development efforts to create an appetite suppressant. However, a 2006 review of Merck’s internal documents disproves this assumption.5 The authors of the review concluded that Merck created and patented MDMA in 1912 as a precursor for a new hemostatic substance (to stop bleeding). The company never tested the pharmacological effects of MDMA at the time. Merck patented MDMA to keep from infringing on an existing patent for a hemostatic substance that had been filed by a German competitor.

The Chemistry of MDMA

The chemical structure of MDMA is similar to methamphetamine (Figure 1).

Figure 1: The chemical structures of MDMA and methamphetamine. MDMA has a methylenedioxy group, and methamphetamine does not.

The synthesis of MDMA begins with compounds that contain a preformed methylendioxyphenyl ring such as piperonal, isosafrole, safrole, and piperonylacetone.6 The original synthesis method used by Merck was brominating safrole to 1-(3,4-methylenedioxyphenyl)-2-bromopropane which was then reacted with methylamine.1,6

Safrole is produced primarily from the sassafras plant found mostly in China, Myanmar, and Cambodia.7 Isosafrole is an isomer of safrole, and piperonal is produced by the oxidation of isosafrole. Piperonal also occurs naturally in several plants, including violets, dill, vanilla, and black pepper.

The illicit manufacturing of MDMA often begins with the precursor 3,4-methylenedioxyphenyl-2-propanone (3,4-MDP-2-P).7 The 3,4-MDP-2-P can be synthesized from safrole, isosafrole, or piperonal.

The Pharmacology of MDMA

About 80% of ingested MDMA is metabolized in the liver, and about 20% is excreted in the urine.8,9 In the body, MDMA can be N-demethylated to form 3,4-methylenedioxyamphetamine (MDA), then O-demethylenated to form 3,4-dihydroxymethamphetamine (HHMA).  HHMA is further metabolized by O-methylation to form 4-hydroxy-3-methoxy-methamphetamine (HMMA). The majority of MDMA metabolites (especially HMMA which is highly unstable) form conjugates with sulfate glucuronic acid before excretion.10,11

MDMA binds to the three synaptic monoamine transporters serotonin, dopamine, and norepinephrine.12,13 It acts as a releasing agent of these neurotransmitters via its activity at trace amine-associated receptor 1 (TAAR1) and vesicular monoamine transporter 2 (VMAT2).14,15 When MDMA is active at TAAR1, the neurotransmitters move out of the cellular cytosol into the synaptic cleft. MDMA activity at VMAT2 causes the neurotransmitter to move from the synaptic cleft back into the cytosol.

Of the three transporters discussed above, MDMA has the greatest affinity for the serotonin transporter.12 Its affinities for dopamine and norepinephrine be at least 10-fold less. Binding at the serotonin and dopamine transporters is stereoselective with the S-(+) isomer being more potent. No stereoselectivity for the other transporters has been noted.

MDMA has a binding affinity for several classic neurotransmitter receptors, particularly serotonin 5-HT2, α2-adrenergic, muscarinic M1, and histamine H1.13  The compound also binds but has less affinity for M2 muscarinic, α1-adrenergic, ß-adrenergic, 5-HT1, and dopamine D1 and D2 receptors.

The Applications and Potential of MDMA

MDMA-assisted psychotherapy was going on in the US prior to the Drug Enforcement Agency placing it on Schedule I in 1985.16 At the time it concluded, this work was showing that MDMA decreased pain and feelings of fear and anxiety in people while allowing them to remain clear-headed and alert. Research on the therapeutic effects of MDMA has come a long way since then, to the point of clinical trials that are currently underway.

The Multidisciplinary Association for Psychedelic Studies (MAPS) is in the process of spending nearly $27 million dedicated to the pursuit of US Food and Drug Administration (FDA) approval of MDMA as a prescription medicine by 2021. Their first randomized controlled pilot study conducted in 2011 found that “MDMA-assisted psychotherapy can be administered to post-traumatic stress disorder patients without evidence of harm, and it may be useful in patients refractory to other treatments.”17 Currently, MAPS is funding phase 3 clinical trials to evaluate MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD).18 The results of the trial so far have been so promising that in August 2017, the FDA granted breakthrough therapy designation for MDMA for the treatment of PTSD.

There is evidence suggesting that the effects of MDMA in women are different from men. The 2016 US Global Drug Survey found that female British clubbers were 2-3 times more likely to seek emergency treatment than men after using MDMA (ecstasy).19 There was also a 4-fold increase in the last three years in emergency room visits for women who had used MDMA. Researchers theorize that the cause may be related to women’s unique body chemistry.

A 2001 study found the psychoactive effects of MDMA in women were more intense than those of men, possibly due to women being more susceptible to the serotonin-releasing effects of MDMA.20 The effects reported included perceptual changes, thought disturbances, and the fear of loss of body control. The dose of MDMA was positively correlated with the intensity of the effects. Women also had more adverse effects and outcomes from MDMA than men.

Receptor Binding Affinity Data

ReceptorKi (nM)SpeciesRef.
5-HT1A>10000Human23
5-HT1B>10000Human23
5-HT1D>10000Human23
5-HT1E>10000Human23
5-HT2A>10000Rat23
5-HT2B=500Human23
5-HT2C>10000Rat23
5-HT3>10000Human23
5-HT5A>10000Human24
5-HT6>10000Human23
5-HT7>10000Human23
D1>10000Human23
D2>10000Human23
D3>10000Human23
D4>10000Human23
D5>10000Human23
M1>10000Human23
M2>10000Human23
M3=1851Human23
M4=8245Human23
M5=6339Human23
    References
  1. Verfahren zur Darstellung von Alkyloxyaryl-, Dialkyloxyaryl- und Alkylenedioxyarylaminopropanen bzw. deren am Stickstoffmonoalkylierten Derivaten, 1914. German Patent 274,350, filed December 24, 1912, issued May 16, 1914, assigned to E. Merck in Darmstadt, Germany.
  2. Sreenivasan VR. Problems in Identification of Methylenediony and Methoxy Amphetamines. The Journal of Criminal Law, Criminology, and Police Science. 1972;63(2):304. doi:10.2307/1142315
  3. Gaston TR, Rasmussen GT. Identification of 3, 4-methylenedioxymethamphetamine. Microgram. 1972;5:60.
  4. Eichmeier LS, Caplis ME. Forensic chemist. Analytical detective. Analytical Chemistry. 1975;47(9):841A - 844a
  5. Freudenmann RW, Öxler F, Bernschneider‐Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*. Addiction. 2006;101(9):1241-1245. doi:10.1111/j.1360-0443.2006.01511.x
  6. Shulgin AT. History of MDMA. In: Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Topics in the Neurosciences. Springer, Boston, MA; 1990:1-20. doi:10.1007/978-1-4613-1485-1_1
  7. United Nations Office on Drugs and Crime. World Drug Report 2014. United Nations Office on Drugs and Crime; 2014. http://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf.
  8. de la Torre R, Farré M, Roset PN, et al. Human Pharmacology of MDMA: Pharmacokinetics, Metabolism, and Disposition. Therapeutic Drug Monitoring. 2004;26(2):137.
  9. Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol. 2012;86(8):1167-1231. doi:10.1007/s00204-012-0815-5
  10. Segura M, Ortuno J, Farré M, et al. 3, 4-Dihydroxymethamphetamine (HHMA). A Major in Vivo 3, 4-methylenedioxymethamphetamine (MDMA) Metabolite in Humans. Chem Res Toxicol. 2001;14:1203–1208.
  11. Shima N, Kamata H, Katagi M, Tsuchihashi H, Sakuma T, Nemoto N. Direct determination of glucuronide and sulfate of 4-hydroxy-3-methoxymethamphetamine, the main metabolite of MDMA, in human urine. Journal of Chromatography B. 2007;857(1):123-129. doi:10.1016/j.jchromb.2007.07.003
  12. Steele TD, Nichols DE, Yim GK. Stereochemical effects of 3, 4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H] monoamines into synaptosomes from different regions of rat brain. Biochemical pharmacology. 1987;36(14):2297–2303.
  13. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB. Pharmacologic profile of MDMA (3, 4-methylenedioxymethamphetamine) at various brain recognition sites. European journal of pharmacology. 1988;149(1-2):159–163.
  14. Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. Journal of Neurochemistry. 2011;116(2):164-176. doi:10.1111/j.1471-4159.2010.07109.x
  15. Berry MD, Gainetdinov RR, Hoener MC, Shahid M. Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. Pharmacology & Therapeutics. 2017;180:161-180. doi:10.1016/j.pharmthera.2017.07.002
  16. Greer GR, Tolbert R. A Method of Conducting Therapeutic Sessions with MDMA. Journal of Psychoactive Drugs. 1998;30(4):371-379. doi:10.1080/02791072.1998.10399713
  17. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25(4):439-452. doi:10.1177/0269881110378371
  18. Mithoefer MC, Feduccia AA, Jerome L, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology. May 2019. doi:10.1007/s00213-019-05249-5
  19. The Global Drug Survey 2016 Findings | Global Drug Survey. https://www.globaldrugsurvey.com/past-findings/the-global-drug-survey-2016-findings/.
  20. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology. 2001;154(2):161-168. doi:10.1007/s002130000648
  21. MDMA 42542-10-9. ChemIDplus NIH. https://chem.nlm.nih.gov/chemidplus/rn/42542-10-9.
  22. MDMA hydrochloride. PubChem Open Chemistry Database. https://pubchem.ncbi.nlm.nih.gov/compound/71285.
  23. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro. Mol Pharmacol. 2003;63(6):1223-1229. doi:10.1124/mol.63.6.1223
  24. PDSP Database - UNC. https://pdsp.unc.edu/databases/pdsp.php.